Get the Stockscreener App
0.9448
7.37%
-0.0752
Pre-market:
.95
0.0052
+0.55%
Evogene Ltd stock is traded at $0.9448, with a volume of 181.48K.
It is down -7.37% in the last 24 hours and down -12.52% over the past month.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.
See More
Previous Close:
$1.02
Open:
$0.9903
24h Volume:
181.48K
Relative Volume:
0.45
Market Cap:
$8.24M
Revenue:
$6.74M
Net Income/Loss:
$-14.74M
P/E Ratio:
-0.4201
EPS:
-2.2491
Net Cash Flow:
$-18.31M
1W Performance:
-14.11%
1M Performance:
-12.52%
6M Performance:
-24.42%
1Y Performance:
-35.73%
1-Day Range:
$0.91
$1.00
1-Week Range:
$0.91
$1.19
52-Week Range:
$0.91
$2.42
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
0.9448 | 8.89M | 6.74M | -14.74M | -18.31M | -2.2491 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-21 | Initiated | ROTH Capital | Buy |
| Jul-29-21 | Initiated | Aegis Capital | Buy |
| Dec-01-20 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-16-13 | Initiated | Oppenheimer | Outperform |
Evogene Ltd Stock (EVGN) Latest News
Why did EVGN shares drop more than 14% today? - MSN
Evogene Ltd. Expands Google Cloud Collaboration to Integrate AI Agents into ChemPass AI™ - iGrow News
Evogene Secures $3.4 Million Through Warrant Inducement Deal - TipRanks
Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases - Finviz
AI-designed drugs take aim at inflammatory diseases affecting millions - Stock Titan
Evogene expands Google Cloud collaboration to enhance AI platform By Investing.com - Investing.com South Africa
Evogene announces warrant inducement deal for $3.4 million By Investing.com - Investing.com Nigeria
Evogene Enters Warrant Inducement Agreement Amid Stock Decline - Intellectia AI
Why Did EVGN Shares Drop More Than 14% Today? - Asianet Newsable
Evogene announces warrant inducement deal for $3.4 million - Investing.com
Evogene raises $3.4M by cutting warrant price to $1 each - Stock Titan
Evogene stock rises as company expands Google Cloud collaboration - Investing.com India
Evogene Ltd. Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI?? - marketscreener.com
Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI - Finviz
Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™ - PR Newswire
Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds - Finviz
Evogene appoints two professors to scientific advisory board By Investing.com - Investing.com South Africa
Evogene Ltd. Appoints Prof. John J. Irwin and Prof. Dan T. Major to Its Scientific Advisory Board - marketscreener.com
Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board - Finviz
Evogene appoints two professors to scientific advisory board - Investing.com
Evogene, Shanghai Lishan Sign Exclusive Licensing Deal For Global Development of Microbiome Cancer Drug BMC128 - Voice Of HealthCare
Investment Recap: Is Evogene Ltd. in a consolidation phase2025 Price Momentum & High Return Trade Guides - baoquankhu1.vn
Evogene and Lishan Biotech Sign Exclusive Licensing Agreement - Intellectia AI
Evogene subsidiary licenses cancer microbiome therapy to Lishan Biotech By Investing.com - Investing.com Nigeria
Evogene (EVGN) Stock: Stabilizes as BMC128 Deal Targets Renal and Lung Cancer Growth - parameter.io
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer - Finviz
Evogene Joins Forces with Unravel Biosciences to Combat Neurological Disorders - StocksToTrade
Evogene Licenses Microbiome-Based Cancer Therapeutic BMC128 To Shanghai Lishan Biopharmaceuticals - Nasdaq
Evogene stock soars after licensing deal for cancer therapeutic By Investing.com - Investing.com India
Evogene stock soars after licensing deal for cancer therapeutic - Investing.com
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Excl - GuruFocus
Evogene’s Biomica Grants Lishan Biotech Global Rights to Microbiome Cancer Drug BMC128 - TipRanks
Evogene subsidiary licenses cancer microbiome therapy to Lishan Biotech - Investing.com
Earnings Recap: Is Evogene Ltd impacted by rising ratesMarket Growth Report & Capital Protection Trade Alerts - baoquankhu1.vn
Evogene (NASDAQ:EVGN) Shares Cross Below Two Hundred Day Moving Average – What’s Next? - Defense World
Aug Retail: Is Evogene Ltd attractive for institutional investorsJuly 2025 Weekly Recap & Long Hold Capital Preservation Plans - baoquankhu1.vn
Jobs Data: How cyclical is SHOTWs revenue stream2025 Volume Leaders & Safe Capital Growth Stock Tips - baoquankhu1.vn
S P Trends: Is McDonalds Corporation stock technically oversoldIndex Update & Reliable Intraday Trade Alerts - baoquankhu1.vn
MACD Signal: Can Evogene Ltd disrupt its industryPortfolio Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Evogene Announces CFO Resignation and Finance Leadership Transition - TipRanks
Evogene announces CFO resignation and interim appointment By Investing.com - Investing.com Nigeria
Evogene announces CFO resignation and interim appointment - Investing.com
Evogene (NASDAQ: EVGN) plans CFO change as VP Finance steps up to new role - Stock Titan
Evogene Ltd. Announces CFO Changes - marketscreener.com
Breakout Watch: Is Evogene Ltd stock heavily shortedJuly 2025 Intraday Action & Trade Opportunity Analysis Reports - baoquankhu1.vn
US Market Wrap: How Evogene Ltd stock performs in weak economyNew Guidance & Expert Verified Stock Movement Alerts - Bộ Nội Vụ
Published on: 2026-01-11 04:12:19 - Улправда
Portfolio Shifts: Can Evogene Ltd stock sustain market leadershipDividend Hike & Low Risk Entry Point Guides - moha.gov.vn
HOKA Model Insights: Will Evogene Ltd. stock benefit from upcoming earnings reportsTrail vs Road Selection & updated model highlights and notes - Улправда
Is Evogene Ltd. stock undervalued vs historical averages2025 Buyback Activity & Weekly Watchlist for Hot Stocks - Улправда
Why Evogene Ltd. stock appeals to dividend seekers2025 EndofYear Setup & Real-Time Volume Spike Alerts - Улправда
Evogene Ltd Stock (EVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):